Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘cardiology retractions’ Category

“Serious and obvious mistakes” kill paper on heart attacks in rats

with 2 comments

j card pharmA group of researchers in China and the United States have retracted a 2014 paper in the Journal of Cardiovascular Pharmacology after discovering the data were fatally flawed.

The article examined whether the anti-arrhythmia drug zacopride affected cardiac remodeling after heart attack, and came from Bo-We Wu, of Shanxi Medical University, in Taiyuan, and colleagues, including one author from Savannah, Georgia.

Here’s more from the notice for “Activation of IK1 channel by zacopride attenuates left ventricular remodeling in rats with myocardial infarction”:

Read the rest of this entry »

Lancet retracts and republishes cardiology paper with admirable notice

with 4 comments

logo_lancetOne of the papers from a massive heart disease study in China, published in the Lancet, has been retracted and republished after the authors noticed a statistical error.

The article, by authors from Peking Union Medical College in China, Yale University, and elsewhere, presented the results of the China PEACE-Retrospective Acute Myocardial Infarction Study, part of a national initiative to study and improve care for cardiac problems. After being posted online on June 24, 2014, the authors noticed that they’d incorrectly weighed one of the cities in their calculations, which threw off a number of national estimates.

After the corrections were made, the paper was peer-reviewed again, and reviewers stated that despite the mistakes, the original conclusions were sound.

Today is a banner day on Retraction Watch: This is our second excellent example of transparency in 24 hours, and therefore the second entry in our “doing the right thing” category. An editorial lays out exactly what happened, including a timeline, allowing scientists to feel confident they’re basing the next research step on solid and accurate data. (We also appreciate the hat tip to the Committee on Publication Ethics retraction guidelines, which we often send out to editors of bad notices as a gentle reminder.)

Here’s the notice for “ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data”: Read the rest of this entry »

Bad image prompts correction of Harvard-Brigham stem cell paper by Anversa

with 11 comments

circresA group of Harvard stem cell researchers who already have one retraction and an expression of concern now have a correction. This one’s in Circulation Research, and it involves an image that previously had been flagged as suspicious in our comments.

The group is led by Piero Anversa, who as we reported last year is one of two researchers suing Harvard because the institution’s investigation into their work

has cost them millions in a forfeited sale of their company, and job offers.

Read the rest of this entry »

A ewe-turn: Researchers lose sleep, and paper, over miscounted sheep

with 8 comments

Suspicious sheep via John Haslam

Suspicious sheep via John Haslam

A group of Chinese cardiologists at Capital Medical University have done a quick ewe-turn, pulling a paper after mixing up both the author order and wrongly reporting how many sheep were killed in the making of this experiment.

We covered another retraction from the CMU cardiology department in September. The sheep paper was published in October.

Here’s the notice for “Mosaic tissue-engineered porcine pulmonary artery valved conduit: long-term follow-up after implantation in an ovine model”: Read the rest of this entry »

Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

without comments

JHH(Cover).inddA major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension. 

Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.

Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.

The paper, which has been cited three times, according to Thomson Scientific’s Web of Knowledge, had already been subject to a correction in 2013Read the rest of this entry »

Heart journal pulls paper for image manipulation

with 14 comments

cardresCardiovascular Research has retracted a 2010 paper by a group of prominent cardiology researchers in Brazil.

The reason: Image manipulation — which the authors say didn’t materially affect the conclusions of the paper.

The article, “FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex,” came from a group led by Ana Paula Dalla Costa, from the State University of Campinas.

Here’s the abstract of the study, which has been cited 19 times, according to Thomson Scientific’s Web of Knowledge: Read the rest of this entry »

Heart paper will go on, but only in the first of two journals it was published in

with 4 comments

Cardiovascular ResearchA cardiovascular group has retracted a conference proceeding abstract, because it too closely resembled a paper they published prior to the conference.

The last author is baffled as to why the journal couldn’t have made that call before they published the abstract.

Here’s the notice for “Increased beta-adrenergic inotropy in ventricular myocardium from Trpm4 knockout mice”: Read the rest of this entry »

Critics of Poldermans’ work baffled by NEJM stance on DECREASE papers

with 12 comments

EBPOM_00219_M3

Don Poldermans

A pair of researchers who have been calling for the retraction of two papers by cardiology researcher Don Poldermans say the New England Journal of Medicine is  “not justified” “disappointing” in its refusal to pull the articles.

A little background: Poldermans resigned from Erasmus University in 2011 after having been accused of misconduct. Last week, we reported that the European Heart Journal had issued an expression of concern for a 2001 article on which he was first author.

The New England Journal of Medicine added editor’s notes to two of Poldermans’ articles. But as Larry Husten at Forbes reports, the journal has no intention of retracting the papers: Read the rest of this entry »

Written by amarcus41

September 29th, 2014 at 3:00 pm

Notice fails to get to the heart of cardiology retraction

with 5 comments

cmjThis one is a little odd.

A cardiology paper from China has been retracted because “permission to report these discussions was not sought nor obtained,” though it’s unclear what “the discussions” refers to. The person to whom the discussions are attributed to in the retraction, Ji Bingyang, is not an author on the paper, and none of his papers are cited in the retracted article.

Here’s the notice in the Chinese Medical Journal for “A novel rat model of cardiopulmonary bypass for deep hypothermic circulatory arrest without blood priming”:
Read the rest of this entry »

Data questions prompt retraction of PLOS ONE cardiovascular paper

with 2 comments

plosonePLoS One has retracted a 2013 article on atherosclerosis in mice over concerns about the integrity of the data.

The paper, “The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice,” came from a group of researchers in South Korea.

It purported to show that: Read the rest of this entry »